Gogtay, 125 patient aspirin prophylaxis study: 6% higher mortality [p=0.87], 50% lower ventilation [p=0.16], and 49% lower ICU admission [p=0.41] https://c19p.org/gogtay
copied to clipboard
Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia
et al., World Journal of Critical Care Medicine, doi:10.5492/wjccm.v11.i2.92
Retrospective 125 COVID+ hospitalized patients in the USA, showing no significant differences with aspirin prophylaxis.
|
risk of death, 5.9% higher, RR 1.06, p = 0.87, treatment 12 of 38 (31.6%), control 21 of 87 (24.1%), adjusted per study, odds ratio converted to relative risk, multivariable.
|
|
risk of mechanical ventilation, 49.8% lower, RR 0.50, p = 0.16, treatment 5 of 38 (13.2%), control 21 of 87 (24.1%), NNT 9.1, adjusted per study, odds ratio converted to relative risk, multivariable.
|
|
risk of ICU admission, 49.2% lower, RR 0.51, p = 0.41, treatment 9 of 38 (23.7%), control 38 of 87 (43.7%), NNT 5.0, adjusted per study, odds ratio converted to relative risk, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Gogtay et al., 3/9/2022, retrospective, USA, North America, peer-reviewed, 4 authors, study period March 2020 - April 2020.
Contact:
drgogtay@gmail.com.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.